## Renzo Colombo

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10198488/publications.pdf

Version: 2024-02-01

199 papers 8,699 citations

50 h-index 85 g-index

209 all docs 209 docs citations

times ranked

209

6742 citing authors

#	Article	IF	CITATIONS
1	Bladder perforation during transurethral resection of the bladder: a comprehensive algorithm for diagnosis, management and follow-up. Minerva Urology and Nephrology, 2022, 74, .	1.3	7
2	Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration. European Urology Focus, 2022, 8, 1270-1277.	1.6	11
3	Perioperative and oncologic outcomes of open radical nephrectomy and inferior vena cava thrombectomy with liver mobilization and Pringle maneuver for Mayo III level tumor thrombus: single institution experience. Minerva Urology and Nephrology, 2022, 73, .	1.3	2
4	Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration. World Journal of Urology, 2022, 40, 1167-1174.	1.2	9
5	Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors. European Urology Oncology, 2022, 5, 30-41.	2.6	11
6	Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: A multicenter cohort from the European Association of Urology $\hat{a} \in ``Young Academic Urologists. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 195.e27-195.e35.$	0.8	5
7	Quality-of-Life Outcomes in Female Patients With Ileal Conduit or Orthotopic Neobladder Urinary Diversion: 6-Month Results of a Multicenter Prospective Study. Frontiers in Oncology, 2022, 12, 855546.	1.3	4
8	Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer. European Urology Focus, 2021, 7, 1067-1074.	1.6	7
9	Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent. World Journal of Urology, 2021, 39, 1947-1953.	1.2	7
10	The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer. European Urology Oncology, 2021, 4, 829-833.	2.6	20
11	Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer. Journal of the National Cancer Institute, 2021, 113, 48-53.	3.0	30
12	Protocol of the Italian Radical Cystectomy Registry (RIC): a non-randomized, 24-month, multicenter study comparing robotic-assisted, laparoscopic, and open surgery for radical cystectomy in bladder cancer. BMC Cancer, 2021, 21, 51.	1.1	7
13	Association of patients' sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer. World Journal of Urology, 2021, 39, 3337-3344.	1.2	9
14	Multicentre International Study for the Prevention with iAluRil of Radio-induced Cystitis (MISTIC): A Randomised Controlled Study. European Urology Open Science, 2021, 26, 45-54.	0.2	8
15	Factores de riesgo de enfermedad residual en la re-RTU en una gran cohorte de pacientes con enfermedad T1G3. Actas Urológicas Españolas, 2021, 45, 473-473.	0.3	O
16	Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?. European Urology, 2021, 80, 319-322.	0.9	24
17	Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy. Journal of Urology, 2021, 206, 885-893.	0.2	11
18	The Role of Prior Bladder Cancer on Recurrence in Patients Treated with Radical Nephroureterectomy. Clinical Genitourinary Cancer, 2021, , .	0.9	3

#	Article	IF	CITATIONS
19	Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 77.e1-77.e7.	0.8	26
20	How to improve patient selection for neoadjuvant chemotherapy in bladder cancer patients candidate for radical cystectomy and pelvic lymph node dissection. World Journal of Urology, 2020, 38, 1229-1233.	1.2	3
21	Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. World Journal of Urology, 2020, 38, 1959-1968.	1.2	22
22	Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. European Urology, 2020, 77, 439-446.	0.9	228
23	Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. European Urology, 2020, 77, 636-643.	0.9	75
24	Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial. European Urology, 2020, 77, 576-580.	0.9	55
25	Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 studyâ <sup>*</sup> †. Annals of Oncology, 2020, 31, 1755-1763.	0.6	65
26	Hospital care in Departments defined as COVID-free: A proposal for a safe hospitalization protecting healthcare professionals and patients not affected by COVID-19. Archivio Italiano Di Urologia Andrologia, 2020, 92, .	0.4	14
27	Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. European Urology, 2020, 77, 701-710.	0.9	128
28	Sex-specific Alterations in the Urinary and Tissue Microbiome in Therapy-na $\tilde{A}$ -ve Urothelial Bladder Cancer Patients. European Urology Oncology, 2020, 3, 784-788.	2.6	41
29	Perioperative and oncologic outcomes of open radical nephrectomy and inferior vena cava thrombectomy with liver mobilization and Pringle maneuver for Mayo III level tumor thrombus: single institution experience. Minerva Urology and Nephrology, 2020, , .	1.3	3
30	Radical Cystectomy in Pathological T4a and T4b Bladder Cancer Patients: Is There Any Space for Sub Stratification?. Urologia Internationalis, 2019, 102, 269-276.	0.6	9
31	The impact of completeness of last transurethral resection of bladder tumors on the outcomes of radical cystectomy. World Journal of Urology, 2019, 37, 2707-2714.	1.2	6
32	Evaluation of Cause of Death After Radical Cystectomy for Patients With Bladder Cancer: The Impact of Age at the Time of Surgery. Clinical Genitourinary Cancer, 2019, 17, e541-e548.	0.9	6
33	Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2019, 17, 7-14.e3.	0.9	9
34	Adjuvant recMAGE-A3 Immunotherapy After Cystectomy for Muscle-invasive Bladder Cancer: Lessons Learned from the Phase 2 MAGNOLIA Clinical Trial. European Urology Focus, 2019, 5, 849-852.	1.6	2
35	Re: Evaluation of Cause of Death after Radical Cystectomy for Patients with Bladder Cancer: The Impact of Age at the Time of Surgery. Journal of Urology, 2019, 202, 1076-1077.	0.2	0
36	Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy. World Journal of Urology, 2018, 36, 639-644.	1.2	18

#	Article	IF	CITATIONS
37	Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought. World Journal of Urology, 2018, 36, 1621-1627.	1.2	29
38	Pattern of node metastases in patients treated with radical cystectomy and extended or superextended pelvic lymph node dissection due to bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 307.e9-307.e14.	0.8	16
39	Feasibility and Clinical Roles of Different Substaging Systems at First and Second Transurethral Resection in Patients with T1 High-Grade Bladder Cancer. European Urology Focus, 2018, 4, 87-93.	1.6	31
40	Clinical Lymphadenopathy in Urothelial Cancer: A Transatlantic Collaboration on Performance of Cross-sectional Imaging and Oncologic Outcomes in Patients Treated with Radical Cystectomy Without Neoadjuvant Chemotherapy. European Urology Focus, 2018, 4, 245-251.	1.6	24
41	In reply to: Lawless <i>et al</i> . Stalk versus base invasion in <scp>pT</scp> 1 papillary cancers of the bladder: improved substaging system predicting the risk of progression. Histopathology, 2018, 72, 361-362.	1.6	O
42	Perioperative and Oncologic Outcomes of Nephrectomy and Caval Thrombectomy Using Extracorporeal Circulation and Deep Hypothermic Circulatory Arrest for Renal Cell Carcinoma Invading the Supradiaphragmatic Inferior Vena Cava and/or Right Atrium. European Urology, 2018, 73, 793-799.	0.9	33
43	Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. Journal of Clinical Oncology, 2018, 36, 3353-3360.	0.8	474
44	Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy. World Journal of Urology, 2018, 36, 1775-1781.	1.2	15
45	PECULIAR: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (PEM) and epacadostat (EPA), preceding radical cystectomy (Cy), for patients (pts) with muscle-invasive urothelial bladder cancer (MIUBC) Journal of Clinical Oncology, 2018, 36, TPS4595-TPS4595.	0.8	1
46	Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients. Clinical Genitourinary Cancer, 2017, 15, e603-e607.	0.9	27
47	Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 335-341.	0.8	66
48	Impact of Intra- and Postoperative Blood Transfusion on the Incidence, Timing, and Pattern of Disease Recurrence After RadicalÂCystectomy. Clinical Genitourinary Cancer, 2017, 15, e681-e688.	0.9	9
49	Bladder cancer cell growth and motility implicate cannabinoid 2 receptor-mediated modifications of sphingolipids metabolism. Scientific Reports, 2017, 7, 42157.	1.6	28
50	Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 528.e1-528.e5.	0.8	14
51	Impact of Prostate Involvement on Outcomes in Patients Treated with Radical Cystoprostatectomy for Bladder Cancer. Urologia Internationalis, 2017, 98, 290-297.	0.6	8
52	The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 151.e17-151.e23.	0.8	13
53	Predicting local failure after radical cystectomy in patients with bladder cancer: Implications for the selection of candidates at adjuvant radiation therapy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 672.e1-672.e6.	0.8	4
54	Effect of Stage Migration on Bladder Cancer: A Slow but Steady Improvement in Long-Term Survival Rates After Radical Cystectomy in Previous 25 Years. Clinical Genitourinary Cancer, 2017, 15, e223-e228.	0.9	5

#	Article	IF	Citations
55	The surgical management of patients with clinical stage T4 bladder cancer: A single institution experience. European Journal of Surgical Oncology, 2017, 43, 808-814.	0.5	8
56	Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscle-invasive bladder cancer. International Journal of Hyperthermia, 2016, 32, 351-362.	1.1	28
57	Detrusor Muscle in TUR-Derived Bladder Tumor Specimens: Can We Actually Improve the Surgical Quality?. Journal of Endourology, 2016, 30, 400-405.	1.1	17
58	The impact of reâ€transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 highâ€grade/Grade 3 bladder cancer treated with bacille Calmette–Guérin. BJU International, 2016, 118, 44-52.	1.3	110
59	The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non–muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 484.e19-484.e25.	0.8	53
60	Radiofrequency-Induced Thermo-Chemotherapy Effect (Rite) for Non Muscle Invasive Bladder Cancer Treatment: Current Role and Perspectives. Urologia, 2016, 83, 7-17.	0.3	6
61	The Clinical Value of PSA Increase during Intravesical Adjuvant Therapy for Nonmuscle-Invasive Bladder Cancer. Urologia, 2016, 83, 145-148.	0.3	6
62	Usefulness of pT1 substaging in papillary urothelial bladder carcinoma. Diagnostic Pathology, 2016, 11, 6.	0.9	33
63	Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials?. Urologia Internationalis, 2016, 96, 20-24.	0.6	22
64	Preoperative Favorable Characteristics in Bladder Cancer Patients Cannot Substitute the Necessity of Extended Lymphadenectomy During Radical Cystectomy: A Sensitivity Curve Analysis. Urology, 2016, 88, 97-103.	0.5	11
65	Patterns and prognostic significance of clinical recurrences after radical cystectomy for bladder cancer: A 20-year single center experience. European Journal of Surgical Oncology, 2016, 42, 735-743.	0.5	49
66	Incidence and Predictors of 30-Day Readmission in Patients Treated With Radical Cystectomy: A Single Center European Experience. Clinical Genitourinary Cancer, 2016, 14, e341-e346.	0.9	10
67	The Impact of Perioperative Blood Transfusion on Survival of Bladder Cancer Patients Submitted to Radical Cystectomy: Role of Anemia Status. European Urology Focus, 2016, 2, 86-91.	1.6	20
68	Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 256.e7-256.e13.	0.8	20
69	Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer. Clinical Genitourinary Cancer, 2016, 14, e245-e250.	0.9	7
70	A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy. World Journal of Urology, 2016, 34, 207-213.	1.2	14
71	Effect on postoperative survival of the status of distal ureteral margin: The necessity to achieve negative margins at the time of radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 59.e15-59.e22.	0.8	16
72	Comparing longâ€term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy. BJU International, 2016, 117, 604-610.	1.3	68

#	Article	IF	Citations
73	Urinary Bladder Preservation for Muscle-invasive Bladder Cancer: A Survey among Radiation Oncologists of Lombardy, Italy. Tumori, 2015, 101, 174-178.	0.6	9
74	Effect of Allogeneic Intraoperative Blood Transfusion on Survival in Patients Treated With Radical Cystectomy for Nonmetastatic Bladder Cancer: Results From a Single High-Volume Institution. Clinical Genitourinary Cancer, 2015, 13, 562-567.	0.9	37
75	Fifteen-year single-centre experience with three different surgical procedures of nerve-sparing cystectomy in selected organ-confined bladder cancer patients. World Journal of Urology, 2015, 33, 1389-1395.	1.2	34
76	Oncological predictive value of the 2004 World Health Organisation grading classification in primary <scp>T1</scp> nonâ€muscleâ€invasive bladder cancer. A step forward or back?. BJU International, 2015, 115, 267-273.	1.3	23
77	Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy. World Journal of Urology, 2015, 33, 1419-1428.	1.2	19
78	The Clinical Use of Statistical Permutation Test Methodology: A Tool for Identifying Predictive Variables of Outcome. Urologia Internationalis, 2015, 94, 262-269.	0.6	4
79	Case Discussion: A Man with Two Synchronous and Symptomatic Malignancies Related to Smoking: The Case for Surgery. European Urology Focus, 2015, 1, 92-93.	1.6	0
80	Long-term Outcomes of Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer: Results of a Single-institution Series with a Minimum Follow-up of 5 Years. European Urology, 2015, 67, 299-309.	0.9	211
81	Prognostic Factors and Risk Groups in T1G3 Non–Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients. European Urology, 2015, 67, 74-82.	0.9	190
82	Concordance and Clinical Significance of Uncommon Variants of Bladder Urothelial Carcinoma in Transurethral Resection and Radical Cystectomy Specimens. Urology, 2014, 84, 1141-1146.	0.5	42
83	Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: Overview and the Unmet Clinical Need for Alternative Adjuvant Therapy as Studied in the MAGNOLIA Trial. European Urology, 2014, 65, 509-511.	0.9	12
84	Impact of preoperative thrombocytosis on pathological outcomes and survival in patients treated with radical cystectomy for bladder carcinoma. Anticancer Research, 2014, 34, 3225-30.	0.5	33
85	Long-Term Follow-Up Using Testicle-Sparing Surgery for Leydig Cell Tumor. Clinical Genitourinary Cancer, 2013, 11, 321-324.	0.9	45
86	Reply to Manish Garg, Apul Goel and Jai Prakash's Letter to the Editor re: Renzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al. Neoadjuvant Short-term Intensive Intravesical Mitomycin C Regimen Compared with Weekly Schedule for Low-grade Recurrent Non–muscle-invasive Bladder Cancer: Preliminary Results of a Randomised Phase 2 Study. Eur Urol 2012;62:797–802. European Urology, 2013,	0.9	O
87	63, e7-e8.  Lymphadenectomy for Bladder Cancer at the Time of Radical Cystectomy. European Urology, 2013, 64, 266-276.	0.9	62
88	When the Conservative Treatment in High-Risk Non-Muscle Invasive Bladder Cancer Patients should be Abandoned. Urologia, 2013, 80, 48-52.	0.3	0
89	Impact of the introduction of a robotic training programme on prostate cancer stage migration at a single tertiary referral centre. BJU International, 2013, 111, 1222-1230.	1.3	33
90	A novel tool to assess the risk of urinary incontinence after nerveâ€sparing radical prostatectomy. BJU International, 2013, 111, 905-913.	1.3	16

#	Article	IF	Citations
91	Ureteral Endometriosis: Proposal for a Diagnostic and Therapeutic Algorithm with a Review of the Literature. Urologia Internationalis, 2013, 91, 1-9.	0.6	78
92	Serum Sex Steroids Depict a Nonlinear U-Shaped Association with High-Risk Prostate Cancer at Radical Prostatectomy. Clinical Cancer Research, 2012, 18, 3648-3657.	3.2	62
93	Diagnosis and Treatment of Bladder Endometriosis: State of the Art. Urologia Internationalis, 2012, 89, 249-258.	0.6	85
94	Preoperative circulating sex hormones are not predictors of positive surgical margins at open radical prostatectomy. World Journal of Urology, 2012, 30, 533-539.	1.2	6
95	Neoadjuvant Short-term Intensive Intravesical Mitomycin C Regimen Compared with Weekly Schedule for Low-grade Recurrent Non–muscle-invasive Bladder Cancer: Preliminary Results of a Randomised Phase 2 Study. European Urology, 2012, 62, 797-802.	0.9	41
96	Preoperative Erectile Function Represents a Significant Predictor of Postoperative Urinary Continence Recovery in Patients Treated With Bilateral Nerve Sparing Radical Prostatectomy. Journal of Urology, 2012, 187, 569-574.	0.2	35
97	There is no way to identify patients who will harbor small volume, unilateral prostate cancer at final pathology. Implications for focal therapies. Prostate, 2012, 72, 925-930.	1.2	12
98	Performance Characteristics of Computed Tomography in Detecting Lymph Node Metastases in Contemporary Patients with Prostate Cancer Treated with Extended Pelvic Lymph Node Dissection. European Urology, 2012, 61, 1132-1138.	0.9	120
99	Prediction of Functional Outcomes After Nerve-Sparing Radical Prostatectomy: Results of Conditional Survival Analyses. European Urology, 2012, 62, 42-52.	0.9	75
100	Choosing the Best Candidates for Penile Rehabilitation After Bilateral Nerve-Sparing Radical Prostatectomy. Journal of Sexual Medicine, 2012, 9, 608-617.	0.3	35
101	Extended Pelvic Lymph Node Dissection Does Not Affect Erectile Function Recovery in Patients Treated with Bilateral Nerveâ€Sparing Radical Prostatectomy. Journal of Sexual Medicine, 2012, 9, 2187-2194.	0.3	17
102	Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 259-264.	0.8	44
103	Clinical Reliability of the 2004 WHO Histological Classification System Compared With the 1973 WHO System for Ta Primary Bladder Tumors. Journal of Urology, 2011, 186, 2194-2200.	0.2	35
104	Re: Long-Term Outcomes of a Randomized Controlled Trial Comparing Thermochemotherapy With Mitomycin-C Alone as Adjuvant Treatment for Non-Muscle-Invasive Bladder Cancer (NMIBC). Journal of Urology, 2011, 186, 1808-1809.	0.2	1
105	Sex hormoneâ€binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy. BJU International, 2011, 107, 1243-1249.	1.3	11
106	Longâ€term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycinâ€C alone as adjuvant treatment for nonâ€muscleâ€invasive bladder cancer (NMIBC). BJU International, 2011, 107, 912-918.	1.3	169
107	What Is the Definition of a Satisfactory Erectile Function After Bilateral Nerve Sparing Radical Prostatectomy?. Journal of Sexual Medicine, 2011, 8, 1210-1217.	0.3	38
108	The Role of a Combined Regimen With Intravesical Chemotherapy and Hyperthermia in the Management of Non-muscle-invasive Bladder Cancer: A Systematic Review. European Urology, 2011, 60, 81-93.	0.9	166

#	Article	IF	Citations
109	Impact of Venous Tumour Thrombus Consistency (Solid vs Friable) on Cancer-specific Survival in Patients with Renal Cell Carcinoma. European Urology, 2011, 60, 358-365.	0.9	39
110	Pelvic/Retroperitoneal Salvage Lymph Node Dissection for Patients Treated With Radical Prostatectomy With Biochemical Recurrence and Nodal Recurrence Detected by [11C]Choline Positron Emission Tomography/Computed Tomography. European Urology, 2011, 60, 935-943.	0.9	209
111	Preoperative hypogonadism is not an independent predictor of highâ€risk disease in patients undergoing radical prostatectomy. Cancer, 2011, 117, 3953-3962.	2.0	47
112	Are Referral Centers for Non-Muscle-Invasive Bladder Cancer Compliant to EAU Guidelines? A Report from the Vesical Antiblastic Therapy Italian Study. Urologia Internationalis, 2011, 86, 19-24.	0.6	27
113	Can Gemcitabine Instillation Ablate Solitary Low-Risk Non-Muscle-Invasive Bladder Cancer? Results of a Phase II Marker Lesion Study. Urologia Internationalis, 2011, 87, 470-474.	0.6	7
114	Editorial Comment on: HYAL-1 Hyaluronidase: A Potential Prognostic Indicator for Progression to Muscle Invasion and Recurrence in Bladder Cancer. European Urology, 2010, 57, 93-94.	0.9	0
115	Prevention and Management of Complications Following Radical Cystectomy for Bladder Cancer. European Urology, 2010, 57, 983-1001.	0.9	194
116	A Critical Analysis of Orthotopic Bladder Substitutes in Adult Patients with Bladder Cancer: Is There a Perfect Solution?. European Urology, 2010, 58, 374-383.	0.9	52
117	Postoperative Orgasmic Function Increases over Time in Patients Undergoing Nerve-Sparing Radical Prostatectomy. Journal of Sexual Medicine, 2010, 7, 149-155.	0.3	17
118	Predicting Erectile Function Recovery after Bilateral Nerve Sparing Radical Prostatectomy: A Proposal of a Novel Preoperative Risk Stratification. Journal of Sexual Medicine, 2010, 7, 2521-2531.	0.3	102
119	lleal Conduit as the Standard for Urinary Diversion After Radical Cystectomy for Bladder Cancer. European Urology Supplements, 2010, 9, 736-744.	0.1	53
120	Prevention and management of complications following radical cystectomy for bladder cancer. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2010, 36, 642-643.	0.7	2
121	Unsuccessful Investigation of Preoperative Sexual Health Issues in the Prostate Cancer "Coupleâ€∙ Results of a Real-Life Psychometric Survey at a Major Tertiary Academic Center. Journal of Sexual Medicine, 2009, 6, 3347-3355.	0.3	9
122	Editorial Comment on: Defining Early Morbidity of Radical Cystectomy for Patients with Bladder Cancer Using a Standardized Reporting Methodology. European Urology, 2009, 55, 175-176.	0.9	11
123	Are Infertile Men Less Healthy than Fertile Men? Results of a Prospective Case-Control Survey. European Urology, 2009, 56, 1025-1032.	0.9	141
124	Leydig cell tumour of the testis: presentation, therapy, longâ€term followâ€up and the role of organâ€sparing surgery in a singleâ€institution experience. BJU International, 2009, 103, 197-200.	1.3	72
125	Combined Thermo-Chemotherapy for Recurrent Bladder Cancer After Bacillus Calmette-Guerin. Journal of Urology, 2009, 182, 1313-1317.	0.2	109
126	Is Sperm Banking of Interest to Patients With Nongerm Cell Urological Cancer Before Potentially Fertility Damaging Treatments?. Journal of Urology, 2009, 182, 1101-1107.	0.2	15

#	Article	IF	CITATIONS
127	Renal Sinus Fat Invasion in pT3a Clear Cell Renal Cell Carcinoma Affects Outcomes of Patients Without Nodal Involvement or Distant Metastases. Journal of Urology, 2009, 181, 2027-2032.	0.2	47
128	Nerve-Sparing Radical Retropubic Prostatectomy in Patients Previously Submitted to Holmium Laser Enucleation of the Prostate for Bladder Outlet Obstruction Due to Benign Prostatic Enlargement. European Urology, 2008, 53, 1180-1185.	0.9	35
129	Prognostic Value of Lymph Node Dissection in Patients with Muscle-Invasive Transitional Cell Carcinoma of the Upper Urinary Tract. European Urology, 2008, 53, 794-802.	0.9	137
130	Radical Prostatectomy for Incidental (Stage T1a–T1b) Prostate Cancer: Analysis of Predictors for Residual Disease and Biochemical Recurrence. European Urology, 2008, 54, 118-125.	0.9	61
131	Editorial Comment on:Comparison of Complications in Three Incontinent Urinary Diversions. European Urology, 2008, 54, 833-834.	0.9	0
132	Impact of Surgical Volume on the Rate of Lymph Node Metastases in Patients Undergoing Radical Prostatectomy and Extended Pelvic Lymph Node Dissection for Clinically Localized Prostate Cancer. European Urology, 2008, 54, 794-804.	0.9	61
133	Radical Nephrocapsulectomy and Caval Thrombectomy with Extracorporeal Circulation and Deep Hypothermic Circulatory Arrest in Right Anterior Minithoracotomy: A Minimally Invasive Approach. Urology, 2008, 71, 957-961.	0.5	11
134	Combined treatment with local thermo-chemotherapy for non muscle invasive bladder cancer. The present role in the light of acquired data and preliminary cumulative clinical experiences. Archivio Italiano Di Urologia Andrologia, 2008, 80, 149-56.	0.4	7
135	A reappraisal of the role of vesicourethral anastomosis biopsy in patient candidates for salvage radiation therapy after radical prostatectomy. Radiotherapy and Oncology, 2007, 82, 30-37.	0.3	16
136	Conservative Surgical Therapy for Leydig Cell Tumor. Journal of Urology, 2007, 178, 507-511.	0.2	69
137	Secondary scrotal lymphedema: A novel microsurgical approach. Microsurgery, 2007, 27, 655-656.	0.6	28
138	Editorial Comment on: PO Stage at Radical Cystectomy for Bladder Cancer is Associated with Improved Outcome Independent of Traditional Clinical Risk Factors. European Urology, 2007, 52, 774-775.	0.9	0
139	Re: Lymphatic Invasion is a Prognostic Factor for Bladder Cancer Treated with Radical Cystectomy. European Urology, 2007, 52, 1797-1798.	0.9	1
140	Photodynamic diagnosis for follow-up of carcinoma in situ of the bladder. Therapeutics and Clinical Risk Management, 2007, 3, 1003-7.	0.9	9
141	Radical Prostatectomy After Previous Prostate Surgery: Clinical and Functional Outcomes. Journal of Urology, 2006, 176, 2459-2463.	0.2	104
142	Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. BJU International, 2006, 98, 329-334.	1.3	126
143	General versus spinal anesthesia with different forms of sedation in patients undergoing radical retropubic prostatectomy: Results of a prospective, randomized study. International Journal of Urology, 2006, 13, 1185-1190.	0.5	22
144	Bilateral Renal Mass Suggestive of Cancer. European Urology, 2006, 49, 746-747.	0.9	0

#	Article	IF	CITATIONS
145	Bilateral Renal Mass Suggestive of Cancer: Part 2. European Urology, 2006, 49, 918-920.	0.9	0
146	Holmium Laser Enucleation of the Prostate Versus Open Prostatectomy for Prostates > 70g: 24-Month Follow-up. European Urology, 2006, 50, 563-568.	0.9	331
147	Update of the minimally invasive therapies for benign prostatic hyperplasia. Current Opinion in Urology, 2005, 15, 49-53.	0.9	15
148	A critical analysis of laser prostatectomy in the management of benign prostatic hyperplasia. BJU International, 2005, 96, 736-739.	1.3	8
149	Pfannenstiel versus Vertical Laparotomy in Patients Undergoing Radical Retropubic Prostatectomy with Spinal Anesthesia: Results of a Prospective, Randomized Trial. European Urology, 2005, 47, 202-208.	0.9	15
150	Effect of Ethanol and Red Wine on Ochratoxin A-Induced Experimental Acute Nephrotoxicity. Journal of Agricultural and Food Chemistry, 2005, 53, 6924-6929.	2.4	21
151	Primary and Pure Neuroendocrine Tumor of the Prostate. European Urology, 2004, 45, 166-170.	0.9	21
152	Sexual Dysfunction is Common in Women with Lower Urinary Tract Symptoms and Urinary Incontinence: Results of a Cross-Sectional Study. European Urology, 2004, 45, 642-648.	0.9	316
153	Preliminary European Results of Local Microwave Hyperthermia and Chemotherapy Treatment in Intermediate or High Risk Superficial Transitional Cell Carcinoma of the Bladder. European Urology, 2004, 46, 65-72.	0.9	144
154	Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients. International Journal of Radiation Oncology Biology Physics, 2004, 59, 674-683.	0.4	42
155	In regard to Cozzarini et al.: Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: A single-institute experience of 415 patients (Int J Radiat Oncol Biol) Tj ETQq1 I	1 <b>@.7</b> 8431	4 <b>g</b> BT /Ove
156	Overall Clinical Outcomes After Nerve and Seminal Sparing Radical Cystectomy for the Treatment of Organ Confined Bladder Cancer. Journal of Urology, 2004, 171, 1819-1822.	0.2	89
157	Holmium Laser Enucleation Versus Transurethral Resection of the Prostate. Are Histological Findings Comparable?. Journal of Urology, 2004, 171, 1203-1206.	0.2	73
158	Monofocal and plurifocal high-grade prostatic intraepithelial neoplasia on extended prostate biopsies: factors predicting cancer detection on extended repeat biopsy. Urology, 2004, 63, 1105-1110.	0.5	56
159	General versus spinal anesthesia in patients undergoing radical retropubic prostatectomy: results of a prospective, randomized study. Urology, 2004, 64, 95-100.	0.5	52
160	Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology, 2004, 63, 466-471.	0.5	104
161	Laparoscopic Nerve- and Seminal-Sparing Cystectomy with Orthotopic Ileal Neobladder: The First Three Cases. European Urology, 2003, 44, 567-572.	0.9	33
162	Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: preliminary clinical experience. Critical Reviews in Oncology/Hematology, 2003, 47, 127-139.	2.0	36

#	Article	IF	CITATIONS
163	Multicentric Study Comparing Intravesical Chemotherapy Alone and With Local Microwave Hyperthermia for Prophylaxis of Recurrence of Superficial Transitional Cell Carcinoma. Journal of Clinical Oncology, 2003, 21, 4270-4276.	0.8	244
164	Vestibular Flap Urethroplasty for Strictures of the Female Urethra. Urologia Internationalis, 2002, 69, 12-16.	0.6	67
165	A Prospective Study Comparing Paroxetine Alone Versus Paroxetine Plus Sildenafil in Patients With Premature Ejaculation. Journal of Urology, 2002, 168, 2486-2489.	0.2	160
166	Re: Sexuality Preserving Cystectomy And Neobladder: Initial Results. Journal of Urology, 2002, 167, 1803-1803.	0.2	0
167	Urological complications after simultaneous renal and pancreatic transplantation. The European Journal of Surgery, 2002, 168, 609-613.	1.0	9
168	Re: Sexuality Preserving Cystectomy And Neobladder: Initial Results. Journal of Urology, 2002, , 1803.	0.2	0
169	Thermo–Chemotherapy and Electromotive Drug Administration of Mitomycin C in Superficial Bladder Cancer Eradication. European Urology, 2001, 39, 95-100.	0.9	70
170	Herniation of the amniotic sac into the bladder through a vesico-uterine fistula in the 32nd week of pregnancy. British Journal of Obstetrics and Gynaecology, 2001, 108, 1300-1301.	0.9	2
171	RECONFIGURATION OF THE SEVERELY FIBROTIC PENIS WITH A PENILE IMPLANT. Journal of Urology, 2001, 166, 1782-1786.	0.2	41
172	LAPAROSCOPIC CROSS-TRIGONAL COHEN URETERONEOCYSTOSTOMY: NOVEL TECHNIQUE. Journal of Urology, 2001, 166, 1811-1814.	0.2	143
173	RE: NERVE AND SEMINAL SPARING RADICAL CYSTECTOMY WITH ORTHOTOPIC URINARY DIVERSION FOR SELECT PATIENTS WITH SUPERFICIAL BLADDER CANCER: AN INNOVATIVE SURGICAL APPROACH. Journal of Urology, 2001, 166, 1402-1402.	0.2	0
174	NERVE AND SEMINAL SPARING RADICAL CYSTECTOMY WITH ORTHOTOPIC URINARY DIVERSION FOR SELECT PATIENTS WITH SUPERFICIAL BLADDER CANCER: AN INNOVATIVE SURGICAL APPROACH. Journal of Urology, 2001, 165, 51-55.	0.2	75
175	Counselling the patient with prostate cancer about treatment-related erectile dysfunction. Current Opinion in Urology, 2001, 11, 611-617.	0.9	25
176	Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. British Journal of Clinical Pharmacology, 2001, 52, 273-278.	1.1	73
177	Herniation of the amniotic sac into the bladder through a vesico-uterine fistula in the 32nd week of pregnancy. BJOG: an International Journal of Obstetrics and Gynaecology, 2001, 108, 1300-1301.	1.1	1
178	LOCAL MICROWAVE HYPERTHERMIA AND INTRAVESICAL CHEMOTHERAPY AS BLADDER SPARING TREATMENT FOR SELECT MULTIFOCAL AND UNRESECTABLE SUPERFICIAL BLADDER TUMORS. Journal of Urology, 1998, 159, 783-787.	0.2	48
179	Pathologic features and clinical outcome after anatomic radical prostatectomy by transcoccygeal approach. Urology, 1997, 49, 392-399.	0.5	O
180	Plasma mitomycin C concentrations determined by HPLC coupled to solid-phase extraction. Clinical Chemistry, 1997, 43, 615-618.	1.5	23

#	Article	IF	CITATIONS
181	Effects of Short-Term Treatment with the $\hat{l}\pm(1)$ -Blocker Alfuzosin on Urodynamic Pressure/Flow Parameters in Patients with Benign Prostatic Hyperplasia. European Urology, 1997, 32, 47-53.	0.9	47
182	Neoadjuvant Combined Microwave Induced Local Hyperthermia and Topical Chemotherapy Versus Chemotherapy Alone for Superficial Bladder Cancer. Journal of Urology, 1996, 155, 1227-1232.	0.2	87
183	Dynamic Gadolinium-Enhanced Magnetic Resonance Imaging in Staging of Superficial Bladder Cancer. Journal of Urology, 1996, 155, 1594-1599.	0.2	48
184	Imaging of Renal Cell Carcinoma with Gadolinium-Enhanced Magnetic Resonance: Radiological and Pathological Study. Urologia Internationalis, 1995, 54, 121-127.	0.6	8
185	An original balloon-expanding urethral suture guide for radical prostatectomy. Urology, 1995, 46, 562-564.	0.5	6
186	Original Articles: Bladder Cancer: A New Approach Using Local Combined Microwave Hyperthermia and Chemotherapy in Superficial Transitional Bladder Carcinoma Treatment. Journal of Urology, 1995, 153, 959-963.	0.2	67
187	Detubularized Sigmoid Colon For Bladder Replacement After Radical Cystectomy. Journal of Urology, 1994, 152, 1409-1412.	0.2	22
188	Transrectal Prostatic Hyperthermia and Urinary Retention Secondary to Benign Prostatic Hyperplasia: A 2-Year Follow-Up Study. Journal of Endourology, 1992, 6, 261-264.	1.1	4
189	Transrectal Microwave Hyperthermia for Benign Prostatic Hyperplasia: Long-Term Clinical, Pathological and Ultrastructural Patterns. Journal of Urology, 1992, 148, 321-325.	0.2	53
190	Transrectal Microwave Hyperthermia for Advanced Prostate Cancer: Long-Term Clinical Results. Journal of Urology, 1992, 148, 342-345.	0.2	31
191	Transrectal Hyperthermia-Induced Histological and Ultrastructural Changes of Human Benign Prostatic Hyperplasia Tissue. European Urology, 1992, 22, 74-78.	0.9	8
192	Combined Intravesical Chemotherapy with Mitomycin C and Local Bladder Microwave-Induced Hyperthermia as a Preoperative Therapy for Superficial Bladder Tumors. European Urology, 1991, 20, 204-210.	0.9	40
193	Multimodal Therapy for Stones in Pelvic Kidneys. Urologia Internationalis, 1991, 46, 29-34.	0.6	15
194	Long Term Experience with the Prostatic Spiral for Urinary Retention due to Benign Prostatic Hyperplasia. Scandinavian Journal of Urology and Nephrology, 1991, 25, 21-24.	1.4	14
195	Morphodynamic and biochemical assessment of seminal plasma in patients who underwent local prostatic hyperthermia. Prostate, 1990, 16, 325-330.	1.2	16
196	Local Bacillus Calmette-Guerin Therapy for Superficial Bladder Cancer: Clinical, Histological and Ultrastructural Patterns. Scandinavian Journal of Urology and Nephrology, 1990, 24, 191-198.	1.4	6
197	Histological and Ultrastructural Evaluation of Extracorporeal Shock Wave Lithotripsy-Induced Acute Renal Lesions: Preliminary Report. European Urology, 1989, 16, 207-211.	0.9	29
198	Pembrolizumab as Neoadjuvant Therapy Preceding Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Group, Phase 2 Study. SSRN Electronic Journal, 0, , .	0.4	12

#	Article	IF	CITATIONS
199	Multicentre International Study for the Prevention with Ialuril $\hat{A}^{\otimes}$ of Radio-Induced Cystitis (MISTIC): A Randomised Controlled Study. SSRN Electronic Journal, 0, , .	0.4	O